Go Pro
→ Ticker Revealed: Pre-IPO Access to 'Next Elon Musk' Company (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amgen Inc. stock logo
AMGN
Amgen
$414.62
-0.1%		$370.57
$269.77
▼
$421.79
$223.20B0.412.71 million shs3,166 shs
Novavax, Inc. stock logo
NVAX
Novavax
$8.06
+0.2%		$8.51
$6.20
▼
$11.97
$1.32B2.474.59 million shs11,505 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amgen Inc. stock logo
AMGN
Amgen
0.00%+1.04%+13.36%+28.00%+40.05%
Novavax, Inc. stock logo
NVAX
Novavax
0.00%+1.26%-1.95%-9.85%-15.97%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amgen Inc. stock logo
AMGN
Amgen
$414.62
-0.1%		$370.57
$269.77
▼
$421.79
$223.20B0.412.71 million shs3,166 shs
Novavax, Inc. stock logo
NVAX
Novavax
$8.06
+0.2%		$8.51
$6.20
▼
$11.97
$1.32B2.474.59 million shs11,505 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amgen Inc. stock logo
AMGN
Amgen
0.00%+1.04%+13.36%+28.00%+40.05%
Novavax, Inc. stock logo
NVAX
Novavax
0.00%+1.26%-1.95%-9.85%-15.97%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amgen Inc. stock logo
AMGN
Amgen
2.35
Hold$372.39-10.18% Downside
Novavax, Inc. stock logo
NVAX
Novavax
2.20
Hold$13.0061.23% Upside

Current Analyst Ratings Breakdown

Latest AMGN and NVAX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/14/2026
Amgen Inc. stock logo
AMGN
Amgen
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetEqual Weight$360.00 ➝ $380.00
8/10/2026
Amgen Inc. stock logo
AMGN
Amgen
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$343.00 ➝ $388.00
8/7/2026
Amgen Inc. stock logo
AMGN
Amgen
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$345.00 ➝ $405.00
8/6/2026
Amgen Inc. stock logo
AMGN
Amgen
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeBuy (B-) ➝ Buy (B)
8/6/2026
Amgen Inc. stock logo
AMGN
Amgen
Sanford C. Bernstein logo
Sanford C. Bernstein
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetMarket Perform$335.00 ➝ $345.00
8/6/2026
Novavax, Inc. stock logo
NVAX
Novavax
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
8/5/2026
Amgen Inc. stock logo
AMGN
Amgen
Scotiabank logo
Scotiabank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$385.00 ➝ $450.00
8/5/2026
Amgen Inc. stock logo
AMGN
Amgen
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$420.00 ➝ $440.00
8/5/2026
Amgen Inc. stock logo
AMGN
Amgen
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$420.00 ➝ $452.00
8/5/2026
Amgen Inc. stock logo
AMGN
Amgen
Scotiabank logo
Scotiabank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetSector Outperform$385.00 ➝ $450.00
8/5/2026
Amgen Inc. stock logo
AMGN
Amgen
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetHold$340.00 ➝ $362.00
(Data available from 8/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amgen Inc. stock logo
AMGN
Amgen
$38.10B5.88$33.76 per share12.28$16.08 per share25.78
Novavax, Inc. stock logo
NVAX
Novavax
$1.12B1.18$3.52 per share2.29($0.79) per share-10.21
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amgen Inc. stock logo
AMGN
Amgen
$7.71B$16.0925.6617.103.8622.95%124.14%13.18%11/3/2026 (Estimated)
Novavax, Inc. stock logo
NVAX
Novavax
$440.30M-$1.52N/AN/AN/A-59.87%-14.82%-13.35%11/5/2026 (Estimated)

Latest AMGN and NVAX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
Novavax, Inc. stock logo
NVAX
Novavax
-$0.3798-$0.32+$0.0598-$0.32$52.51 million$56.70 million
8/4/2026Q2 2026
Amgen Inc. stock logo
AMGN
Amgen
$5.62$6.29+$0.67$4.37$9.43 billion$10.05 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Amgen Inc. stock logo
AMGN
Amgen
$10.082.43%+8.27%62.65%14 Years
Novavax, Inc. stock logo
NVAX
Novavax
N/AN/AN/AN/AN/A

Latest AMGN and NVAX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/30/2026
Amgen Inc. stock logo
AMGN
Amgen
quarterly$2.522.6%8/21/20268/21/20269/11/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amgen Inc. stock logo
AMGN
Amgen
4.44
1.37
1.13
Novavax, Inc. stock logo
NVAX
Novavax
N/A
2.33
2.30

Institutional Ownership

CompanyInstitutional Ownership
Amgen Inc. stock logo
AMGN
Amgen
76.50%
Novavax, Inc. stock logo
NVAX
Novavax
53.04%

Insider Ownership

CompanyInsider Ownership
Amgen Inc. stock logo
AMGN
Amgen
0.85%
Novavax, Inc. stock logo
NVAX
Novavax
1.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Amgen Inc. stock logo
AMGN
Amgen
31,500540.63 million536.04 millionOptionable
Novavax, Inc. stock logo
NVAX
Novavax
1,990164.95 million162.31 millionOptionable

Recent News About These Companies

Novavax, Inc. (NASDAQ:NVAX) Given Consensus Rating of "Hold" by Brokerages
August 16 at 2:28 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30963459
Novavax, Inc. (NASDAQ:NVAX) Given Consensus Rating of "Hold" by Analysts
August 16 at 2:28 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/novavax-inc-nasdaqnvax-given-consensus-rating-of-hold-by-analysts-2026-08-16/
Bank of America Corp DE Cuts Stock Holdings in Novavax, Inc. $NVAX
August 12, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-america-corp-de-cuts-stock-holdings-in-novavax-inc-nvax-2026-08-12/
Novavax (NVAX) Q2 2026
August 8, 2026  |  247wallst.comhttps://247wallst.com/companies/nvax/earnings
Cantor Fitzgerald Sticks to Its Buy Rating for Novavax (NVAX)
August 8, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/3736577/cantor-fitzgerald-sticks-to-its-buy-rating-for-novavax-nvax/
Novavax (NASDAQ:NVAX) Lowered to Hold Rating by Zacks Research
August 8, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/novavax-nasdaqnvax-lowered-to-hold-rating-by-zacks-research-2026-08-08/
Renaissance Technologies LLC Invests $4.05 Million in Novavax, Inc. $NVAX
August 8, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-renaissance-technologies-llc-invests-405-million-in-novavax-inc-nvax-2026-08-08/
NVAX Q2 Earnings & Sales Beat Estimates, '26 Sales Outlook Raised
August 7, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/nvax-q2-earnings-sales-beat-181800274.html
NVAX Q2 Earnings & Sales Beat Estimates, '26 Sales Outlook Raised
August 7, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2971411/nvax-q2-earnings-sales-beat-estimates-26-sales-outlook-raised?cid=cs-stocknewsapi-ft-analyst_blog|earnings_article-2971411
Novavax Q2 Earnings Call Highlights
August 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/novavax-q2-earnings-call-highlights-2026-08-07/
Novavax (NASDAQ:NVAX) Posts Earnings Results, Beats Estimates By $0.06 EPS
August 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/novavax-nasdaqnvax-posts-earnings-results-beats-estimates-by-006-eps-2026-08-06/
Novavax, Inc. (NVAX) Q2 2026 Earnings Call Transcript
August 6, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4932396-novavax-inc-nvax-q2-2026-earnings-call-transcript
Novavax raises 2026 revenue outlook after Q2 beat
August 6, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4627726-novavax-raises-2026-outlook-q2-beat
NVAX Stock Holds Steady As Novavax Lifts Revenue Outlook On Licensing Pivot — Retail Eyes Buyout, More Partnership Deals
August 6, 2026  |  stocktwits.comS
Novavax, Inc. 2026 Q2 - Results - Earnings Call Presentation
August 6, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4932466-novavax-inc-2026-q2-results-earnings-call-presentation
Novavax (NASDAQ:NVAX) Exceeds Q2 CY2026 Expectations
August 6, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/novavax-nasdaq-nvax-exceeds-q2-131818805.html
Are Medical Stocks Lagging Novavax (NVAX) This Year?
August 6, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/medical-stocks-lagging-novavax-nvax-134001983.html
Novavax (NVAX) Reports Q2 Loss, Tops Revenue Estimates
August 6, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/novavax-nvax-reports-q2-loss-135011458.html
Novavax tops forecasts and raises revenue outlook as Sanofi collaboration progresses
August 6, 2026  |  investorshub.advfn.comhttps://investorshub.advfn.com/market-news/article/33640/novavax-tops-forecasts-and-raises-revenue-outlook-as-sanofi-collaboration-progresses
ADMA Q2 Earnings Meet, Revenues Miss on Bivigam Weakness
August 6, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/adma-q2-earnings-meet-revenues-145000204.html
Novavax (NVAX) Reports Q2 Loss, Tops Revenue Estimates
August 6, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2969892/novavax-nvax-reports-q2-loss-tops-revenue-estimates?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_4-2969892

New MarketBeat Followers Over Time

Media Sentiment Over Time

Amgen stock logo

Amgen NASDAQ:AMGN

$414.62 -0.59 (-0.14%)
As of 09:34 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Novavax stock logo

Novavax NASDAQ:NVAX

$8.06 +0.01 (+0.16%)
As of 09:34 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas